Interactions between tumor and immune cells either enhance or inhibit cancer progression. We show here that Stat3 signaling within the tumor microenvironment induces a procarcinogenic cytokine, IL-23, while inhibiting a central anticarcinogenic cytokine, IL-12, thereby shifting the balance of tumor immunity toward carcinogenesis. Stat3 induces expression of IL-23, which is mainly produced by tumor-associated macrophages, via direct transcriptional activation of the IL-23/p19 gene. Furthermore, Stat3 inhibits NF-kB/cRel-dependent IL-12/p35 gene expression in tumor-associated dendritic cells. Tumor-associated regulatory T cells (Tregs) express IL-23 receptor, which activates Stat3 in this cell type, leading to upregulation of the Treg-specific transcription factor Foxp3 and the immunosuppressive cytokine IL-10. These results demonstrate that Stat3 promotes IL-23-mediated procarcinogenic immune responses while inhibiting IL-12-dependent antitumor immunity.
INTRODUCTION
The transcription factor Stat3 is constitutively activated in diverse cancers (Yu and Jove, 2004) , and its activation in tumors enhances transcription of genes associated with cell-cycle progression, cell survival, angiogenesis, and immune evasion (Yu and Jove, 2004; Yu et al., 2007) . In addition to tumor cells, Stat3 is constitutively activated within many immune cell types in the tumor microenvironment, including dendritic cells (DCs) and macrophages (Kortylewski et al., 2005) . Ablating Stat3 in myeloid cells allows efficient CD8 + T cell infiltration into tumors while inhibiting accumulation of regulatory T cells (Tregs) (Kortylewski et al., 2005) . Activated Stat3 suppresses antitumor immunity by inhibiting the expression of many cytokines and chemokines important for stimulating antitumor immunity and by upregulating production of several immunosuppressive factors, including IL-10 and VEGF (Takeda et al., 1999; Wang et al., 2004) . These immunosuppressive factors are not only Stat3 target genes but also Stat3 activators (Yu et al., 2007) . In order to further explore the mechanisms by which Stat3 mediates tumor immunosuppression, we evaluated its role in the regulation of two closely related cytokines, IL-23 and IL-12, which play critical but opposing roles in tumor immunity. IL-12, a heterodimer composed of a and b subunits (termed p35 and p40, respectively), promotes antitumor immunity via activation of natural killer (NK) cells and T helper 1 (Th1) T cells and is characterized by production of interferon-g, another important cytokine in antitumor immunity (Gerosa et al., 2002; Kaplan et al., 1998; Shankaran et al., 2001; Trinchieri, 2003) . IL-12 further promotes the expansion and activity of cytotoxic T lymphocytes (CTLs) both directly and indirectly by Th1 cells (Colombo and Trinchieri, 2002) . IL-23, a more recently discovered IL-12 family member, is composed of the p40 subunit in common with IL-12, paired with a unique p19 subunit (Oppmann et al., 2000) . Similarly, IL-12 receptor (IL-12R) and IL-23 receptor (IL-23R) share a common b subunit, which is paired with a unique a subunit for SIGNIFICANCE Recent studies suggest that two related cytokines, IL-23 and IL-12, play opposite roles in carcinogenesis. However, the underlying mechanisms regulating the balance between these cytokines in the tumor microenvironment have not been elucidated. Mechanisms by which IL-23 promotes tumor immune evasion also remain to be explored. Our results reveal that Stat3 signaling in the tumor microenvironment regulates the IL-12/IL-23 balance and, furthermore, that IL-23 enhances the immunosuppressive activity of regulatory T cells within the tumor microenvironment, in part via IL-23 receptor-dependent Stat3 activation. Because Stat3 is a point of convergence for signaling pathways commonly activated in cancer, our data reveal a mechanism by which oncogenic pathways regulate the immune microenvironment to promote tumor development. each receptor (Parham et al., 2002) . While IL-23 was originally thought to possess proinflammatory properties similar to IL-12, analysis of mice with selective knockout of the IL-12/p35 gene versus the IL-23/p40 gene revealed distinct functions for these two cytokines. In particular, a number of experimental autoimmune diseases were shown to be dependent on IL-23 and not on IL-12 Ghilardi et al., 2004; Langrish et al., 2005; Murphy et al., 2003) . IL-23 has also been shown to promote the expansion of a distinct lineage of helper T cell, termed Th17 (Langrish et al., 2005) . Th17 cells are characterized by production of a number of specific cytokines not produced by Th1 or Th2 cells, including IL-17A, IL-17F, IL-21, and IL-22. Interestingly, Stat3 has also been documented to be an essential transcriptional regulator of IL-17, IL-21, and IL-22 production by Th17 cells Harris et al., 2007; Laurence et al., 2007; O'Shea and Murray, 2008; Wei et al., 2007; Zheng et al., 2007; Zhou et al., 2007) .
An opposite role in carcinogenesis has recently been reported for IL-23 compared to IL-12 (Langowski et al., 2006 (Langowski et al., , 2007 . Carcinogen-induced tumor formation was greater in IL-12/p35 KO mice, confirming the physiologic antitumor role of IL-12; however the opposite effect was observed in IL-23/p19 KO mice (Langowski et al., 2006) . Whereas IL-12 facilitated tumor (Langowski et al., 2006) . While these results suggest a procarcinogenic role for IL-23 production within tumors, its mechanisms of action in tumor regulation have not been elucidated. We therefore investigated how IL-23 and IL-12 expression are differentially regulated in the tumor microenvironment and how IL-23 further propagates tumor immunosuppressive effects.
RESULTS

Role of Stat3 in the Differential Expression of IL-23 and IL-12 in Tumors
We assessed IL-23 and IL-12 protein secretion by B16 tumor cells in vitro and B16 tumors growing in vivo after implantation into C57BL/6 mice. B16 tumor cells and a second melanoma tumor line, C4, cultured in vitro secreted very little of either cytokine as detected by ELISA ( Figure 1A , left). B16 tumors growing in vivo were dissociated into single-cell suspensions that consisted of tumor cells as well as hematopoietically derived cells comprising the tumor microenvironment. Similar to in vitro results, only a small amount of IL-23 or IL-12 secretion was detected by ELISA when the unfractionated cell suspensions were cultured (Figures 1A and 1B, left) . When the tumor-associated myeloid component was sorted by fluorescence-activated cell sorting (FACS) into macrophages (CD11b , high levels of IL-23 were found to be produced by the tumor-associated macrophages (MACs; Figure 1A , middle), with much lower levels produced by tumor-infiltrating DCs ( Figure 1A, right) . Western blot data demonstrated that IL-23 was also detectable in CD11b + cells isolated from tumors and tumor-draining lymph nodes ( Figure 1C ). Virtually no IL-12 was secreted either by unfractionated tumors or by purified tumor-associated macrophages or splenic DCs as determined by ELISA ( Figure 1B ). (Kortylewski et al., 2005) . By 24 hr after poly(I:C) treatment, there was no evidence of residual activation of either DCs or macrophages as measured by either cell membrane markers or cytokine production (Kortylewski et al., 2005) . Hematopoietic Stat3 ablation significantly reduced IL-23 production by B16 tumor-associated macrophages ( Figure 1A ). In contrast, IL-12 production was upregulated in B16 tumors from mice with hematopoietic Stat3 knockout. The majority of IL-12 expression came from the tumor-associated DCs infiltrating B16 tumors ( Figure 1B ). Thus, these data implied that Stat3 signaling drives IL-23 production from the tumor-associated macrophages while restraining IL-12 production by tumor-associated DCs. This effect was specific for the tumor microenvironment since there was no significant production of either IL-12 or IL-23 by splenic macrophages or DCs regardless of whether the Stat3 gene was ablated.
To test the generality of our findings that Stat3 in tumor stromal myeloid cells contributed to regulating IL-23 and IL-12 expression in tumors, we performed similar experiments using MC38 colon carcinoma ( Figure 1D ) and MB49 bladder carcinoma (Figure 1E ) models. In vivo experiments showed that the growth of MC38 tumors was inhibited by Stat3 ablation in myeloid cells (see Figure S1 available online), confirming previous data in B16 and MB49 tumor models (Kortylewski et al., 2005) . Consistent with our results in the B16 tumor model, ablating Stat3 in myeloid cells decreased production of IL-23 by macrophages within MC38 and MB49 tumors ( Figures 1D and 1E) . While the overall level of IL-23 secretion by MC38 and MB49 tumorinfiltrating macrophages in control Stat3 flox/flox mice was lower than that observed in B16 tumors, the IL-23 that was produced was clearly Stat3 dependent. Likewise, the DCs isolated from MC38 and MB49 tumors showed increased secretion of IL-12 following induced Stat3 ablation. The level of IL-12 secretion by DCs isolated from MC38 and MB49 tumors did not reach the levels observed in the B16 tumor model, but the increases observed with hematopoietic Stat3 knockout were highly reproducible. Multiple factors likely contribute to the differences in magnitude of IL-23 and IL-12 production by tumor-associated macrophages and Stat3 À/À tumor-associated DCs, respectively, in the different tumors. Previous studies indicated that IL-12 expression can be induced in Stat3 À/À splenic DCs by Toll-like receptor (TLR) activation (Kortylewski et al., 2005) . Dying tumor cells have also been shown to stimulate DC IL-12 production (Apetoh et al., 2007) . or Stat3 À/À splenic macrophages ( Figure 2A ). Despite low levels (26-and 79-fold lower in B16 and C4 cells, respectively, relative to tumor-infiltrating macrophages), IL-23/p19 mRNA in the tumor cells was reduced more than 80% by Stat3 siRNA knockdown ( Figure S2A ). These results suggested that Stat3 positively regulates IL-23 at the transcriptional level in different cell types. In order to determine whether this transcriptional regulation was direct, we performed luciferase reporter and chromatin immunoprecipitation (ChIP) analyses. First, 3T3 cells were transfected with a luciferase expression vector driven by the IL-23/p19 promoter (À1159 to +160). Dual-luciferase activity was enhanced significantly by cotransfection with a constitutively active Stat3 mutant, Stat3C ( Figure 2B ). B16 cell transfection with the IL-23/ p19 promoter-driven luciferase reporter gene resulted in progressively decreased luciferase activity with successively increasing amounts of Stat3 siRNA ( Figure 2C , top). Cotransfection with NF-kB/p65 siRNA also resulted in decreased luciferase activity, with the greatest suppression occurring upon cotransfection with both Stat3 and NF-kB siRNAs ( Figure 2C , bottom). These results indicate that NF-kB/p65, which is also constitutively activated in B16 like in many other cancers, participates in IL-23/p19 transcription.
We next performed ChIP analysis on B16 cells using primers for the IL-23/p19 promoter. Both Stat3 and NF-kB/p65 were associated with the IL-23/p19 promoter ( Figure 3A) . While it was difficult to obtain enough tumor-associated macrophages to perform ChIP analysis, ChIP of total tumors growing in vivo as well as tumor-draining lymph nodes demonstrated Stat3 binding to the IL-23/p19 promoter along with NF-kB/p65 ( Figures 3B and 3C ). NF-kB/p65 binding to the IL-23/p19 promoter was also higher in tumor-draining lymph nodes relative to nondraining lymph nodes ( Figure 3B ). Hematopoietic Stat3 ablation resulted in a decreased ChIP signal for both Stat3 and NF-kB/p65 on the IL-23/p19 promoter in growing B16 tumors ( Figure 3C ).
Stat3
Inhibits NF-kB/c-Rel-Mediated IL-12/p35 Gene Expression Real-time PCR demonstrated that Stat3 reciprocally downregulated IL-12/p35 transcription in whole B16 tumors growing in hematopoietic Stat3 KO mice ( Figure 4A , left), in tumor-associated myeloid cells ( Figure 4A , right), and in cultured B16 tumor cells after siRNA transfection ( Figure S2B ). The NF-kB family transcription factor c-Rel has been demonstrated to be essential for transcription of IL-12/p35 (Grumont et al., 2001 ) and other genes important for DC activation (Wang et al., 2007) . However, we found that levels of active c-Rel were low in growing tumors ( Figure 4B Figure 6A shows that tumor-infiltrating Tregs from wild-type mice contained significant amounts of pStat3, while no pStat3 was detected in tumor-infiltrating Tregs from CD4-Cre/Stat3 flox/flox mice. Consistent with an important role for Stat5 in maintaining Tregs , we found that B16 tumor-infiltrating Tregs also displayed high Stat5 activity ( Figure 6A ). Since IL-23 is known to stimulate both Stat3 and Stat5 (Parham et al., 2002) 
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Stat3 Regulates IL-23/IL-12 Balance in Tumors evaluated directly whether IL-23R signaling impacts Tregs in the tumor microenvironment and whether this directly enhances B16 tumor growth in vivo. IL-23R blockade affected tumor-infiltrating Tregs in a manner similar but not identical to T cell-specific Stat3 ablation ( Figures 7A and 7B ). Anti-IL-23R-treated mice displayed a modest but significant reduction in number of tumor-infiltrating Tregs compared with control antibody-treated mice. However, Foxp3 levels were diminished after anti-IL-23R treatment ( Figure 7A , right), as was IL-10 production ( Figure 7B ). While these results are consistent with a role for IL-23-driven Stat3 activation in tumor-infiltrating Tregs, additional IL-23R-dependent signaling pathways (such as Stat5) are likely operative in tumor-infiltrating Tregs. In addition, other cytokines in the tumor microenvironment (such as IL-10) could additionally contribute to Stat3 activation in tumor-infiltrating Tregs. The effects of IL-23 within the tumor microenvironment indeed translate to an overall enhancement of tumor growth, as in vivo IL-23R blockade resulted in a significant reduction in tumor growth relative to isotype control antibody ( Figure 7C ).
DISCUSSION
The immune system acts as an extrinsic tumor suppressor (Dunn et al., 2005; Kaplan et al., 1998; Koebel et al., 2007) . However, tumors acquire various mechanisms to facilitate immune escape (Dunn et al., 2002; Zou, 2005 ). Our results demonstrate that Stat3 signaling in the tumor microenvironment shifts inflammation from an antitumor IL-12 program to a tumor-enhancing IL-23 program via transcriptional activation of the IL-23-specific p19 gene and concomitant transcriptional suppression of the IL-12-specific p35 gene. Stat3 appears to coactivate the p19 promoter with NF-kB/p65. In contrast, Stat3 also appears to suppress c-Rel in tumors, thereby reducing binding of c-Rel to the IL-12/ p35 promoter. This is in agreement with a recent report indicating that NF-kB subunits have unique roles in regulating gene expression in DCs (Wang et al., 2007) . The p50 and c-Rel subunits were found to be critical for the induction of T cell stimulatory gene expression, whereas the NF-kB/p65 subunit regulated expression of a distinct group of inflammatory genes, some of which are procarcinogenic (Wang et al., 2007) . While Stat3 transcriptionally activates the IL-23/p19 gene in both tumor cells and myeloid cells within the tumor microenvironment, the major source of Stat3-driven IL-23 is tumor-associated macrophages. Stat3 restrains IL-12 transcription in both tumors and infiltrating myeloid cells, though the majority of IL-12-producing cells in the absence of Stat3 activity are tumor-associated DCs. It is notable that, while these effects of Stat3 are not observed systemically, they appear to be operative in tumor-draining lymph nodes. We are currently testing the hypothesis that a preponderance of IL-23 production relative to IL-12 production by antigen-presenting cells in tumor-draining lymph nodes ultimately skews the differentiation of tumor-specific T cells, possibly leading to dominance of Treg and Th17 responses over antitumor Th1 responses.
IL-12 has been validated in numerous studies as a central cytokine in antitumor immunity and antiviral immunity due to its
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Stat3 Regulates IL-23/IL-12 Balance in Tumors role in activating NK cell, Th1 cell, and CTL responses (Trinchieri, 2003) . The emergence of a second IL-12 family member, IL-23, which shares the p40 subunit with IL-12, has significantly altered our view of autoimmune disease since a number of murine autoimmune syndromes originally thought to be IL-12 dependent are instead IL-23 dependent. These more recent studies have suggested that IL-12-driven immunity is not only qualitatively distinct from IL-23-driven immunity but may also be mutually antagonistic. This notion also pertains to tumor immunity as emphasized by Langowski et al. (2006) , who showed that tumorigenesis is diminished in IL-23/p19 KO mice and increased in IL-12/p35 KO mice. The studies presented here support the notion that IL-23 has a procarcinogenic role in contrast to the well-established anticarcinogenic role of IL-12. Importantly, our findings indicate that Stat3 signaling in both the tumor and the hematopoietic/immune microenvironment of the tumor is critical in shifting the balance from IL-12 to IL-23 production.
An additional unexpected finding of our study was the upregulation of IL-23R in tumor-associated Tregs. Although the underlying mechanism responsible for IL-23R upregulation in tumor-associated Tregs remains to be elucidated, our limited data indicate that the increase in IL-23R expression in tumor Tregs correlates with Stat3 activity. In addition to its central role in IL-23 upregulation, Stat3 appears to also play a role in IL-23R signaling within the tumor microenvironment. The role for Stat3 signaling in IL-10 production by Tregs has not been previously appreciated, although a recent report demonstrates that IL-27-driven IL-10 production by T cells is Stat3 dependent (Stumhofer et al., 2007) . While T cell-specific Stat3 ablation also diminished the number of tumor-infiltrating Th17 cells, this cell population is relatively minor in the B16 system. Recent studies have indicated that Th17 can contribute to tumor progression (Kryczek et al., 2007) ; however, it appears that, at least with B16 melanoma, the major role of T cell-specific Stat3 signaling (and also IL-23R signaling) lies within the Treg compartment. Indeed, ablation of Tregs has been shown to significantly enhance antitumor responses in B16 melanoma (Sutmuller et al., 2001; Turk et al., 2004) . Whether IL-23R-dependent Stat3 signaling has a larger role in Th17 responses in other tumor systems remains to be determined. IL-23R signals through multiple other Stats, which also undoubtedly play a role in how IL-23 modulates the tumor microenvironment. For example, IL-23R also activates Stat5, which O'Shea and colleagues demonstrated to be very important in Treg expansion and possibly also differentiation . Indeed, tumor-infiltrating Tregs have high levels of tyrosine-phosphorylated Stat5. In this context, it was somewhat surprising that Stat3 signaling appears to enhance Foxp3 expression by tumor-infiltrating Tregs. This finding contrasts with studies suggesting that Stat3 activation (driven by IL-6 or IL-27) inhibits differentiation to the Treg lineage (Huber et al., 2008; Laurence et al., 2007) . However, the role of Stat3 in Foxp3 gene regulation may be quite distinct in tumor-infiltrating Tregs (where the cytokine milieu and ambient signals are quite distinct) versus naive T cells being induced into various differentiation pathways in vitro. Indeed, Pallandre et al. (2007) have demonstrated that, similar to our findings here, Stat3 ablation decreases Foxp3 expression by Tregs in a graft-versus-host disease model. Zorn et al. (2006) showed that both Stat3 and Stat5 can bind to a Stat consensus site in the Foxp3 promoter. Thus, the role of Stat3 in regulating Foxp3 expression by Tregs appears to be context dependent. In the context of the signals present within the tumor microenvironment, Stat3 activity in Tregs appears to upregulate Foxp3 levels, which Flavell and colleagues have shown to be important in maintaining Tregs' inhibitory functions (Wan and Flavell, 2007) .
It should also be emphasized that in addition to IL-23, at least two other cytokines, IL-6 and IL-10, appear to play an important role in enhancing cancer progression (Yu et al., 2007) . These cytokines are somewhat interlinked in that they are all Stat3 inducible and their receptors activate Stat3 (O'Shea and Murray, 2008) . While much has been written about the role of IL-6 and IL-10 in promoting tumorigenesis and inhibiting antitumor immunity, our data focus attention on IL-23 as an important mediator of procarcinogenesis by Stat3 signaling.
EXPERIMENTAL PROCEDURES Cells
Mouse B16 melanoma cells were purchased from the American Type Culture Collection. Mouse C4 melanoma, MB49 bladder carcinoma, and MC38 colon carcinoma cells were generous gifts from J. Fidler (MD Anderson Cancer Center), T. Ratliff (University of Iowa), and M. Shurin (University of Pittsburgh), respectively. DC2.4 cells were originally obtained from K. Rock (University of Massachusetts Medical School). The generation of v-Src-transformed BALB/c 3T3 fibroblasts has been described previously (Wang et al., 2004) .
In Vivo Experiments
Mice were maintained and experimental procedures were performed under pathogen-free conditions in accordance with established institutional guidelines and approved protocols from the Research Animal Care Committees of the City of Hope and Johns Hopkins University. We obtained Mx1-Cre mice from The Jackson Laboratory, CD4-Cre mice from Taconic, and Stat3 flox/flox mice from S. Akira and K. Takeda (Osaka University). All transgenic mice were on a C57BL/6J background. Generation of mice with Stat3 À/À hematopoietic cells by the inducible Mx1-Cre recombinase transgenic system has been described previously (Kortylewski et al., 2005) . We generated CD4-Cre/Stat3 flox/flox mice by standard interbreeding procedures. We verified specific Stat3 deletion in T cells by PCR using primer sets that distinguish Stat3, Stat3 loxP , and Stat3-deleted alleles and by FACS analysis of Stat3 phosphorylation in IL-6-treated T cells. For tumor challenge, we injected 1 3 10 5 B16 or 5 3 10 5 MB49 or MC38 tumor cells subcutaneously into 7-to 8-week-old wild-type or transgenic mice, and tumor growth was monitored three times per week. For IL-23R neutralization experiments in vivo, mice were treated with 250 mg of anti-IL-23Ra antibodies (R&D Systems) injected intraperitoneally every third day during the course of the experiment, starting from the day of tumor inoculation. Mice were sacrificed 2 weeks after tumor inoculation. We prepared single-cell suspensions of spleen, lymph node, or tumor tissues by mechanic dispersion followed by collagenase D/DNase I treatment as described previously (Kortylewski et al., 2005) . antibodies in combination with magnetic nanoparticles from StemCell Technologies as described previously (Kortylewski et al., 2005) . For IL-12 and IL-23 measurement by ELISA (eBioscience), we cultured the enriched cell populations for 24 hr to collect supernatants. Equal protein amounts of lysates prepared from enzymatically digested tumors and/or tumor-draining lymph nodes were analyzed by western blotting using antibodies specific to IL-23/ p19 (R&D Systems), phospho-S503-c-Rel (Thermo Scientific), and b-actin (Sigma).
Quantitative Real-Time PCR We isolated total RNAs from various cell populations using the RNeasy System (QIAGEN) and then transcribed them into cDNAs using the iScript cDNA Synthesis Kit (Bio-Rad). PCR reactions were set up using specific primer pairs for mouse 
Reporter Gene Assays
We inserted the mouse IL-23/p19 promoter fragment (À1159 to +160) into the XhoI/HindIII site of the pGL3-Basic vector by PCR, generating the pGL3-p19-Pro-luciferase plasmid. For luciferase assays, we cotransfected 0.4 mg/ml pGL3-p19-Pro-luciferase plasmid containing 0.02 mg/ml pRL-TK normalization construct and 0.4 mg/ml of either the indicated pRC plasmid or siRNAs (80 pmol/ml) into BALB/c 3T3 fibroblasts and B16 and C4 mouse melanoma cells using Lipofectamine 2000 (Invitrogen). We analyzed luciferase activity in whole-cell lysates using the Dual-Luciferase Reporter Assay System (Promega) and quantified results using a Mikrotek Laborsysteme microplate reader. Data are presented as firefly luciferase activity normalized to Renilla luciferase activity in each triplicate sample.
Chromatin Immunoprecipitation Assays
We performed chromatin immunoprecipitations using a ChIP assay kit (Upstate Biotechnology) according to the manufacturer's protocol. Briefly, cultured cells were fixed with 1% formaldehyde at 37 C for 10 min before lysis.
For ChIP assays on freshly isolated whole tumors or tumor-draining or distant lymph nodes, prior to crosslinking with formaldehyde, tissues were frozen in liquid nitrogen and homogenized to enable nuclei isolation. We incubated the sonicated chromatin solutions with 2 mg of Stat3-, p65-, or c-Rel-specific antibodies (Santa Cruz) or with control rabbit IgG. Following immunoprecipitation and reversed crosslinking, DNA was extracted and analyzed by PCR using the following primer sets: mouse IL-23/p19 promoter, 5 0 -GGATTCCCGTCCCT CGGTCTC-3 0 (forward) and 5 0 -GGGCCAAGGCGCTTGGCACAG-3 0 (reverse);
mouse IL-12/p35 promoter, 5 0 -GACAGTGGAGGCACCAGGCC-3 0 (forward) and 5 0 -CAGACATCGCTGTCCCGGCG-3 0 (reverse).
Flow Cytometry
For extracellular staining of immune markers, we prepared single-cell suspensions by mechanic dispersion and enzymatic digestion of spleen, lymph node, or tumor tissues. We preincubated 1 3 10 6 freshly prepared cells suspended in a mixture of PBS, 2% fetal calf serum, and 0.1% (w/v) sodium azide with FcgIII/ IIR-specific antibody to block nonspecific binding and stained with different combinations of fluorochrome-coupled antibodies to CD3, CD4, CD25 (BD Biosciences), or IL-23R (Imgenex). Staining with the anti-IL-23R antibody required earlier labeling of the unconjugated antibody with a fluorescent dye, using the Zenon Labeling Kit (Invitrogen). Prior to intracellular staining with antibodies to phosphotyrosine-Stat3 or -Stat5 (BD Biosciences) and Foxp3 (eBioscience), we fixed cells in paraformaldehyde and permeated them in methanol. For intracellular staining of IFN-g, IL-10, and IL-17 (BD Pharmingen), we followed the manufacturer's protocol after 4 hr incubation in the presence of Leukocyte Activation Cocktail (BD Pharmingen). Fluorescence data were collected on a FACSCalibur system (Beckton Dickinson) and analyzed using FlowJo software (Tree Star).
Statistical Analysis
An unpaired t test was used to calculate two-tailed p values to estimate statistical significance of differences between treatment groups. Statistically significant p values are indicated in figures as follows: ***p < 0.001, **p < 0.01, *p < 0.05. Data were analyzed using GraphPad Prism software.
SUPPLEMENTAL DATA
The Supplemental Data include two figures and can be found with this article online at http://www.cancercell.org/supplemental/S1535-6108(08)00437-6.
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